Howard Schiller made Valeant CFO
This article was originally published in Scrip
Valeant Pharmaceuticals has appointed Howard Schiller executive vice-president and chief financial officer, effective 1 December. Mr Schiller, who recently retired from Goldman Sachs after 24 years, most recently serving as chief operating officer for the investment banking division, will take over the position from Philip Loberg, Valeant's interim CFO. Mr Loberg will remain at the company in a different, as yet unspecified, role.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.